Fujisawa, Japan

Nobuki Sakauchi

USPTO Granted Patents = 11 

 


Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • Osaka, JP (2011 - 2013)
  • Fujisawa, JP (2020 - 2022)
  • Kanagawa, JP (2014 - 2023)

Company Filing History:


Years Active: 2011-2025

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):

Title: Nobuki Sakauchi: Innovator in Cancer Therapeutics

Introduction

Nobuki Sakauchi is a prominent inventor based in Fujisawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. With a total of 11 patents to his name, Sakauchi's work is recognized for its potential impact on therapeutic strategies.

Latest Patents

Sakauchi's latest patents include innovative compounds such as nitrogen-containing heterocycles that act as CDK12 inhibitors. These compounds are designed to exhibit superior CDK12 inhibitory action, making them promising candidates for use as prophylactic or therapeutic drugs for cancer and related diseases. The compounds are represented by specific formulas, which detail their chemical structure and potential applications.

Career Highlights

Nobuki Sakauchi is currently associated with Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His work at Takeda focuses on advancing cancer therapies through innovative research and development. His expertise in medicinal chemistry has been instrumental in the creation of new therapeutic agents.

Collaborations

Sakauchi collaborates with notable colleagues, including Hiroshi Banno and Koji Ono. Together, they work on various projects aimed at enhancing the efficacy of cancer treatments through innovative drug design.

Conclusion

Nobuki Sakauchi's contributions to cancer therapeutics through his patents and collaborations highlight his role as a key innovator in the pharmaceutical industry. His work continues to pave the way for advancements in cancer treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…